THE VALUE OF GENETIC DIVINATION – STATED PREFERENCES FOR PERSONALIZED INFORMATION FOR REDUCING MORTALITY RISKS

Published Nov 24, 2014
Durham, NC, USA – The advent of genetic testing provides individuals and health care systems the opportunity to acquire information about predispositions to cancers and other diseases.  Whether this information is useful depends on the existence of efficacious health interventions to mitigate any potential risk.  Genetic testing is expensive, and a justification for its inclusion in population-screening or insurance-based systems requires sophisticated economic evaluations. Researchers at RTI International, Duke Clinical Research Institute, and the Center for Engineering and Health at Northwestern University conducted an economic evaluation of genetic test information for colorectal cancer risks using survey data from a representative sample of US residents aged 50 and over.  The evaluation employed conjoint analyses or discrete choice experiments with a conceptual framework to estimate an individual’s personal valuation of genetic tests based on costs for preventing and monitoring colorectal cancer. The monetary equivalent of test information was approximately $1,800 – greater than the unit costs of many types of genetic tests.  While these results discourage the inclusion of genetic testing in large-scale programs at the current costs, testing may be beneficial for particular groups of individuals, such as large, less affluent, and employed households, or even larger populations in the future. The full study, “Valuations of Genetic Test Information for Treatable Conditions: The Case of Colorectal Cancer Screening,” is published in Value in Health.

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×